<DOC>
	<DOCNO>NCT00121862</DOCNO>
	<brief_summary>This study evaluate safety immunogenicity Leish-111f + MPL-SE vaccine adult subject evidence previous exposure Leishmania parasite .</brief_summary>
	<brief_title>Study Evaluate Leish-111f + MPL-SE Vaccine Healthy Adults Not Previously Exposed Leishmania Parasite</brief_title>
	<detailed_description>Cutaneous leishmaniasis disfigure disease progress mucosal leishmaniasis , serious possibly fatal form Leishmania disease . All available medical therapy require week treatment cause significant toxicity . It appear Leishmania infection eliminate prevented T helper 1 immune response . These finding argue vaccine generates T helper 1 response parasite prevent infection disease . This phase 2 , randomize , double blind , placebo-controlled study evaluate safety , tolerability immunogenicity Montenegro skin test ( MST ) -negative healthy adult investigational vaccine develop prophylaxis cutaneous leishmaniasis . The vaccine , identify Leish-111f + MPL-SE , consist recombinant three-antigen Leishmania polyprotein ( Leish-111f , 10 μg ) together adjuvant MPL-SE ( 25 μg ) . In addition , safety immunogenicity vaccine compare Leish-111f protein ( 10 μg ) give alone . The vaccine , Leish-111f protein alone placebo give study subject three time 4 week interval .</detailed_description>
	<mesh_term>Leishmaniasis</mesh_term>
	<mesh_term>Leishmaniasis , Cutaneous</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Must negative Montenegro skin test ( 0 mm ) Must good general health normal lab value Negative HIV , hepatitis B C History leishmaniasis exposure Leishmania vaccine MPLSE Nursing pregnant female</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>May 2006</verification_date>
	<keyword>Leishmaniasis</keyword>
	<keyword>Subunit Vaccine</keyword>
	<keyword>Prevention</keyword>
	<keyword>T cell</keyword>
</DOC>